Clinical trials: Irritable Bowel
Irritable Bowel Syndrome
An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome
We hypothesize that duloxetine treatment will be associated with improvement in symptoms of IBS, particularly abdominal pain, in individuals without comorbid major depressive disorder.
- Trial name
- NCT00401258
- Testing
- duloxetine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mclean Hospital
Irritable Bowel Syndrome, Abdominal Pain
Comparing a 182mg Colon-targeted-delivery Peppermint Oil Capsule (Tempocol-ColoPulse®) and a 182mg Enteric-coated Peppermint Oil Capsule (Tempocol®), a Pharmacokinetic Study
This is a pilot study to compare the relative bioavailability between two peppermint oil formulations, namely a ileocolonic release peppermint oil and an small intestinal release peppermint oil (Tempocol®).
- Conditions
- Irritable Bowel Syndrome, Abdominal Pain, Colonic Diseases, Visceral Pain
- Trial name
- NCT02291445
- Testing
- Menthae piperitae aetheroleum/peppermint oil (enteric coated capsule), Menthae piperitae aetheroleum/peppermint oil (colon-targeted-delivery capsule)
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Irritable Bowel Syndrome Characterized by Constipation
A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)
The objective of this trial is to determine the effect of linaclotide on abdominal girth in IBS-C participants with the baseline symptoms of abdominal bloating and an increased abdominal girth.
- Trial name
- NCT02837783
- Testing
- Linaclotide
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Irritable Bowel Syndrome
Ibodutant for Relief of Irritable Bowel Syndrome (IRIS)
The purpose of the study is to evaluate the benefit of treatment with oral dose of Ibodutant (code: MEN 15596) on IBS symptoms and the safety and tolerability of this therapy.
- Trial name
- IRIS (NCT00761007)
- Testing
- Ibodutant
- Where
- 6 sites in Denmark, Germany and 4 more
- Volunteers
- 554 people
- Sponsor
- Menarini Group
Gastrointestinal Diseases
Gastrointestinal Myoelectric Activity Protocol, the G-Tech EEnG Protocol
A feasibility study for monitoring and recording gastrointestinal (GI) myoelectric activity in subjects with suspected or diagnosed irritable bowel syndrome (IBS) and reports of GI pain and asymptomatic subjects without IBS and…
- Trial name
- NCT01697397
- Testing
- Recording of Myoelectric Signals
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- G-Tech Corporation
Irritable Bowel Syndrome With Diarrhea
12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea.
- Trial name
- IRIS-3 (NCT02107196)
- Testing
- Ibodutant 10 mg
- Where
- 127 sites in United States, Bulgaria and 9 more
- Volunteers
- 535 people
- Sponsor
- Menarini Group
IBS - Irritable Bowel Syndrome
Zemedy Application for Irritable Bowel Syndrome
The purpose of the study is investigate the effectiveness of Zemedy, a mobile application that enables the digital delivery of a CBT program to people with IBS.
- Trial name
- NCT04723056
- Testing
- Use of Zemedy Application
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Stanford University
Irritable Bowel Syndrome With Diarrhea
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
This is a randomized, double-blind, placebo-controlled, 2-arm parallel group study. After qualifying for the study and signing informed consent, patients will undergo a two-week observation period during which stool consistency…
- Trial name
- NCT02757105
- Testing
- BEKINDA
- Where
- 16 sites in United States
- Volunteers
- 127 people
- Sponsor
- RedHill Biopharma Limited
Irritable Bowel Syndrome, Generalized Anxiety Disorder
An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder
The investigators propose to evaluate the effectiveness of duloxetine in treating subjects with both Irritable Bowel Syndrome (IBS) and Generalized Anxiety Disorder (GAD).
- Trial name
- NCT00961298
- Testing
- Duloxetine
- Volunteers
- 17 people
- Sponsor
- West Penn Allegheny Health System
Dyspepsia, Irritable Bowel Syndrome
A Randomized, Single Centre, Double-blind, Parallel, Sham-controlled Pilot Study Using gammaCore®-G
A randomized, sham-controlled, single-centre pilot investigation designed to compare two parallel groups, gammaCore®-G (active treatment) and a sham, (inactive) treatment in subjects with FGIDs.
- Trial name
- NCT02388269
- Testing
- gammaCore®-G
- Where
- United Kingdom
- Volunteers
- 91 people
- Sponsor
- ElectroCore INC
Peristomal Skin Complication
Preliminary Evaluation of CASTLE Barrier Prototype UK
The purpose of this study is to provide preliminary assessment of the safety and performance of a novel barrier formulation (CASTLE) in a small population of subjects with irritated peristomal skin.
- Trial name
- NCT01530087
- Testing
- CASTLE barrier
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- Hollister Incorporated
Irritable Bowel Syndrome With Diarrhea
Eluxadoline Bile Acid Malabsorption (BAM) Study
This study will evaluate the possibility of a differential effect of eluxadoline on altered bowel function in Irritable Bowel Syndrome with Diarrhea (IBS-D) participants with and without evidence of Bile Acid Malabsorption (BAM).
- Trial name
- NCT03441581
- Testing
- Eluxadoline
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Allergan
Irritable Bowel Syndrome
Effect of a Cannabinoid Agonist on Colonic Sensory Functions in Patients With Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) affects about 15% of the U.S. population. There are still no effective and safe medications approved for the treatment of abdominal pain associated with bowel symptoms in IBS.
- Trial name
- NCT01786109
- Testing
- Dronabinol
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Michael Camilleri
Constipation-predominant Irritable Bowel Syndrome
Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome
In this study the investigators aim to compare the efficacy of neomycin to a combination of rifaximin and neomycin in the treatment of C-IBS subjects with methane on their breath test.
- Trial name
- C-IBS (NCT00945334)
- Testing
- Neomycin, Rifaximin
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Mark Pimentel, MD
Cystic Fibrosis, Irritable Bowel Syndrome
Neuromodulation for Children With Cystic Fibrosis Experiencing Chronic Abdominal Pain
Chronic abdominal pain is extremely common in individuals with Cystic Fibrosis (CF). Therapy for chronic abdominal pain is very limited and generally consists of osmotic laxatives or drugs that are used to treat irritable bowel…
- Conditions
- Cystic Fibrosis, Irritable Bowel Syndrome, Chronic Pain
- Trial name
- NCT05515250
- Testing
- Use of neurostimulation device
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- St. Louis University
Diarrhea-predominant Irritable Bowel Syndrome
Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg
Irritable bowel syndrome is a complex condition with a high unmet medical need for effective and safe treatment options. Lacteol® is a lactobacillus product used for adjunctive and symptomatic treatment of diarrhea.
- Trial name
- NCT01358708
- Testing
- LACTEOL® 340 mg
- Where
- 8 sites in France, Germany
- Volunteers
- 26 people
- Sponsor
- Forest Laboratories
Constipation, Chronic Idiopathic Constipation
The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation
Constipation is a common gastrointestinal motility disorder that is often chronic, negatively affects patients' daily lives. Constipation occurs when bowel movements become difficult or less frequent.This study is being done to…
- Conditions
- Constipation, Chronic Idiopathic Constipation, Irritable Bowel Syndrome With Constipation
- Trial name
- NCT03054506
- Testing
- CSP01, Carboxymethylcellulose (CMC)
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Massachusetts General Hospital
Irritable Bowel Syndrome
Irritable Bowel Syndrome (IBS) Functional Magnetic Resonance Imaging (fMRI) With Desipramine
Individuals with irritable bowel syndrome (IBS) may experience abdominal pain as a result of pain signals in the bowel and how these signals are processed in the brain.
- Trial name
- NCT00880594
- Testing
- Desipramine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Non-Constipation Irritable Bowel Syndrome
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.
- Trial name
- TARGET 1 (NCT00731679)
- Testing
- Rifaximin
- Where
- 96 sites in United States, Canada
- Volunteers
- 623 people
- Sponsor
- Bausch Health Americas, Inc.
Functional Gastrointestinal Disorders, Irritable Bowel Syndrome
Does Improving Vagal Tone Increase Mitochondrial Bioenergetics
This study evaluates the effect of auricular neurostimulation on mitochondrial bioenergetics and inflammation through vagal nerve modulation via non-invasive percutaneous electrical nerve field stimulator in children with…
- Conditions
- Functional Gastrointestinal Disorders, Irritable Bowel Syndrome, Dyspepsia, Functional Abdominal Pain Syndrome
- Trial name
- NCT03931330
- Testing
- Percutaneous neurostimulation
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Medical College of Wisconsin